Clinical trials: Regorafenib
Colorectal Cancer Metastatic
Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC
The aim of this clinical trial is to find out whether Regorafenib and Sintilimab in combination with electroacupuncture works in treating participants with microsatellite stable (MSS) advanced colorectal cancer who have failed…
- Trial name
- NCT06456515
- Testing
- Regorafenib and Sintilimab in combination with electroacupuncture
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First People's Hospital of Changzhou
KRAS and NRAS Wild-type Colorectal Cancer
Regorafenib + Panitumumab for Colorectal Cancers
Evaluate the safety of regorafenib and panitumumab
- Trial name
- NCT02199223
- Testing
- regorafenib + panitumumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Utah
Liver Transplant; Complications, Hepatocarcinoma
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
1. Explore the impact of postoperative administration of multi-kinase inhibitors (including sorafenib, lenvatinib, and regorafenib) in conjunction with bevacizumab on post-transplant recurrence, overall survival, and drug safety…
- Conditions
- Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma, High-Risk Cancer
- Trial name
- NCT06041490
- Testing
- multi-kinase inhibitors in combination with bevacizumab
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Peking Union Medical College Hospital
Colorectal Cancer Metastatic
Zinc Supplement in Regorafenib Treated mCRC Patient
Phase II randomized trial to investigate whether supplementation of zinc decreases the incidence of HFSR that occurs after treatment of tyrosine kinase inhibitor, regorafenib.
- Trial name
- ZnCORRECT (NCT03898102)
- Testing
- Regorafenib, Zinc gluconate supplement
- Volunteers
- 65 people
- Sponsor
- Chang Gung Memorial Hospital
CRC
Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM
This study is a single-arm, open-label, multicenter clinical study to evaluate the efficacy and safety of Candonilimab (AK104) combined with Regorafenib for the treatment of MSS colorectal liver metastasis.
- Trial name
- NCT06455254
- Testing
- Candonilimab (AK104), Regorafenib
- Where
- 3 sites in China
- Volunteers
- 44 people
- Sponsor
- Jin-hong Chen
Hepatocellular Carcinoma
Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
The goal of this clinical trial is to evaluate the efficacy and safety of cardonilizumab injection combined with TKI in second-line treatment of advanced hepatocellular carcinoma.
- Trial name
- NCT06363006
- Testing
- TKI+Cardunilimab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Gastrointestinal Stromal Tumors (GISTs)
Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs
Randomized, placebo-controlled, phase III study of regorafenib 160 mg once daily on intermittent dosing schedule of 3 weeks on treatment followed by 1 weeks off demonstrated the significant benefit of regorafenib in terms of PFS…
- Trial name
- NCT02889328
- Testing
- Regorafenib
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Asan Medical Center
Colorectal Cancer Liver Metastases
Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM
The incidence of colorectal cancer liver metastasis is high and the prognosis is poor. Improving the treatment effect of colorectal cancer liver metastasis is the key to improving the prognosis of colorectal cancer patients.
- Trial name
- NCT05485909
- Testing
- Radiofrequency ablation, Regorafenib and Toripalimab Combination
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC
To investigate efficacy and toxicity of regorafenib after treatment with atezolizumab and bevacizumab combination
- Trial name
- HCC (NCT05134532)
- Testing
- regorafenib
- Where
- 2 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- CHA University
Colorectal Cancer
[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
Regorafenib is approved in the treatment for metastatic colorectal cancer patients who have been progressed after standard therapies, however, there has not been a predictive biomarker.
- Trial name
- NCT02175095
- Testing
- Regorafenib, [18F]FLT-PET, [18F]FDG-PET
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Asan Medical Center
Adenocarcinoma of the Gastroesophageal Junction, Stage IIB Esophageal Adenocarcinoma
Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery
This randomized phase II trial studies how well regorafenib works in treating patients with cancer of the esophagus or gastroesophageal junction that has spread from where it started to nearby tissue or lymph nodes and have…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Stage IIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma
- Trial name
- NCT02234180
- Testing
- Regorafenib
- Where
- 10 sites in United States
- Volunteers
- 3 people
- Sponsor
- Academic and Community Cancer Research United
Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma
Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer
This phase II trial studies how well the combination of botensilimab, balstilimab and regorafenib works compared to botensilimab and balstilimab in treating patients with microsatellite stable colorectal cancer that may have…
- Conditions
- Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma, Advanced Rectal Adenocarcinoma, Metastatic Colon Adenocarcinoma
- Trial name
- NCT06575725
- Testing
- Balstilimab, Biopsy, Biospecimen Collection
- Sponsor
- City of Hope Medical Center
Gastric/Gastroesophageal Junction Adenocarcinoma
Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Gastric/Gastroesophageal Junction Adenocarcinoma
A single-arm, Phase II clinical study protocol of Apatolimab Tovolimab in combination with regorafenib and chemotherapy as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma
- Trial name
- NCT07148427
- Testing
- Iparomlimab and Tuvonralimab combination with regorafenib and chemotherapy
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Metastatic Colorectal Cancer
Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC
The purpose of this study is to assess the safety and tolerability of different dose-escalation approaches of regorafenib in mCRC patients.
- Trial name
- RE-ARRANGE (NCT02835924)
- Testing
- Regorafenib
- Where
- Spain
- Volunteers
- 299 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
HCC
Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma
This is a Phase 2/3 study evaluating the efficacy and safety of Pracytarabine versus regorafenib in patients with advanced hepatocellular carcinoma (HCC) who have experienced treatment failure with standard systemic therapies…
- Trial name
- NCT07300488
- Testing
- Pracytarabine, regorafenib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Non-small Cell Lung Carcinoma, Urothelial Carcinoma
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
With the increased availability of next-generation sequencing, oncologists are starting to incorporate genomic profiling into routine care of cancer patients.
- Conditions
- Non-small Cell Lung Carcinoma, Urothelial Carcinoma, Gastrointestinal Carcinoma, Non-colon, Upper Aerodigestive Tract Carcinoma
- Trial name
- NCT02795156
- Testing
- Afatinib, Regorafenib, Cabozantinib
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- SCRI Development Innovations, LLC
Renal Cell Carcinoma, Hepatocellular Carcinoma
Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin
Skin toxicity is a frequently observed side effect in the era of "molecularly targeted therapies". Skin toxicity following administration of protein kinase inhibitors such as sorafenib, regorafenib, lapatinib, sunitinib, and…
- Conditions
- Renal Cell Carcinoma, Hepatocellular Carcinoma, Colorectal Carcinoma
- Trial name
- NCT01466504
- Testing
- skin punch biopsy
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Colorectal Neoplasms
Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer
The purpose of this trial is to quantitatively assess the average amount of physical activity that patients are capable to perform while receiving regorafenib for the treatment of metastatic colorectal cancer.
- Trial name
- REGO-ACT (NCT02347852)
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- Austria
- Volunteers
- 25 people
- Sponsor
- Bayer
Advanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy
A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours
To evaluate the efficacy and safety of Cadonilimab Injection in combination with Regorafenib in the treatment of intermediate to advanced biliary systemic tumours that has failed at least one prior systemic therapy
- Trial name
- NCT05644392
- Testing
- Cadonilimab Injection, Regorafenib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Cancer
A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan
This trial is a registrational Phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-M07D1 in patients with advanced colorectal cancer who have HER2 IHC3+ and have failed prior…
- Trial name
- NCT07730489
- Testing
- BL-M07D1, Regorafenib, Fruquintinib
- Where
- 2 sites in China
- Volunteers
- 130 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.